An interventional study of Reduction and Immobilization in Fracture Distal Radius, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Recruiting at 24 sites in United States. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Wrist Fractures with a site in United States — 12 open to participants now, 19 under way, 1 of them phase 3. Wrist Fractures · United States.
Among the 72 studies in Wrist Fractures with a site in United States, this one is the 3rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2023, is one of 48 with no phase, reaches primary completion later than 18 of the 18 other live ones, and was the 48th registered.
331 studies on the registry are indexed under Wrist Fractures; 71 are open to participants now.
Browse Wrist Fractures studies →12 of the 72 studies in Wrist Fractures with a site in United States are open now. Recruiting first, the newest first:
Nemours Children's Clinic · Sites in United States
Ages 3–18
George Washington University · Sites in United States
Ages 18–110 · Healthy volunteers
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Hand Surgery Associates LLC · Sites in United States
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Wrist Fractures studies recruiting now, 20 (49%) set no upper age limit and 13 (32%) stop at 75 or younger; 7 take children under 18; 6 take healthy volunteers.
This study: 4 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 334 is above the median of 64 across 266 interventional studies indexed under Wrist Fractures.
Median enrollment 52 across the 64 interventional studies, 74 across the 7 observational. Of the 39 that completed or were terminated, 14 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 72 have an industry lead sponsor. The 10 most frequent:
Ann & Robert H Lurie Children's Hospital of Chicago is the lead sponsor of 178 studies on the registry; 25 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Ann & Robert H Lurie Children's Hospital of Chicago has 1 study filed under Wrist Fractures — fewer than ten, so there is no comparison to draw.
6 of the studies in Wrist Fractures with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04113044AO Innovation Translation CenterGo Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® | 2026-12-31 |
| NCT05086224University of UtahHematoma Block Versus Bier Block for Closed Fracture Reduction | 2027-07 |
| NCT04976335University of Colorado, DenverQuantitative and Clinical Assessment of Flexor Tendon Gliding Following Application of a Bioresorbable Hydrogel: A Prospective, Randomized Study in Patients Undergoing Distal Radius Fracture Repair | 2027-07 |
| NCT06251206George Washington UniversityImpact of Early ADL Education on Outcomes Post DRF ORIF | 2027-08 |
| NCT02346929Beth Israel Deaconess Medical CenterHematoma Block for Distal Radius Fracture | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 72 studies in Wrist Fractures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This protocol describes a multicenter, prospective randomized superiority trial with a patient preference cohort comparing functional outcomes between children treated with sedated reduction versus no formal reduction.
INTRODUCTION
Distal radius fractures (DRFs) make up 20-25% of all pediatric fractures (Brudvik 2003, Cooper 2004), and are the most common fractures seen in the emergency department in children in the United States. (Naranje 2016)
The available evidence on distal radius fracture (DRF) reduction/non-reduction is based on case series, observational comparisons, and expert opinions. Displaced metaphyseal distal radius fracture (DRFs) have historically been treated with attempts at closed reduction (under conscious sedation or anesthesia). This approach was supported by retrospective studies and consensus opinion that anatomical alignment was necessary for normal function.(Rockwood 2010 text, Bae 2012 JPO) Furthermore, it is unsettling for physicians and families to see bones overlapped on a radiograph when a straightening procedure can be completed in a straightforward fashion. However, simple immobilization without attempted reduction has recently been reported for management of DRFs in children under age 10.(Crawford 2012) This approach is conceptually supported by the fracture's proximity to the distal radial physis and the remaining growth of the child, which provides significant remodeling potential and can allow for improvement of malalignment as the child grows.(Crawford 2010 JBJSAm, Price 1990 JPO) There is a paucity of literature comparing reduced to non-reduced fractures to guide management. No established or standardized guidelines exist for the optimal management of completely displaced fractures. Surveys have identified widely discrepant recommendations and high practice variation for treatments for identical DRF patterns.(Georgiadis 2019 POSNA or JPO 2020) Although these studies provide preliminary data to support clinical management, the studies lack a control population for comparison, are retrospective, lack randomization, have variable follow-up times and have no standard definitions of outcomes. In addition, the studies used radiographic or non-validated outcome measures to make conclusions, limiting their utility in identifying optimal management.
It appears that children may be undergoing unnecessary procedures, sedations, and anesthetics. The use of anesthesia and sedation has recently come into question as studies examine their effects on cognitive development. (Loepke 2013, Flick 2011) There could be a significant cost savings in terms of procedure costs, hospital costs, and lost time from work if non-procedure management is found to be a non-inferior treatment regimen. The physician investigators want to tell patients that they know why they are proposing treatments, the risks and benefits of the treatment, and use evidence to inform these recommendations and the family's decisions. The proposed trial will compare the effectiveness of alignment under sedation/anesthesia with simple immobilization for management of displaced DRFs in children, providing critical data regarding optimal management of this common fracture. Therefore, this study's primary question is: does anatomic reduction under sedation/anesthesia of DRF result in improved patient outcomes at six months compared to immobilization without attempted reduction?
Multiple reasons exist for comparing these treatment strategies for DRF, including: 1) these are the most common treatments for DRF, 2) the strategies are widely divergent (operative vs. non-operative), and 3) there is a large potential to change clinical practice.
QUALITY ASSURANCE AND QUALITY CONTROL
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.
Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial is conducted and data are generated and biological specimens are collected, documented (recorded), and reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.
For specific details regarding quality assurance and quality control, please see the data management plan.
DATA HANDLING AND RECORD KEEPING
DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.
Clinical data and patient reported outcomes will be entered into REDCap, a 21 CFR Part 11-compliant data capture system provided by the DCRI. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.
SAFETY OVERSIGHT
Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) composed of individuals with the appropriate expertise and knowledge of pediatric orthopaedic surgery usually obtained via an accredited pediatric orthopaedic fellowship. Members of the DSMB should be independent from the study conduct and free of conflict of interest, or measures should be in place to minimize perceived conflict of interest. The DSMB will meet at least semiannually to assess safety data on each arm of the study. The DMSB will operate under the rules of an approved charter that will be written and reviewed at the organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to NIAMS.
Statistical Hypotheses:
The null hypothesis is that there is no difference in PROMIS UE (CAT) at 1 year between arms. The alternative hypothesis is that there is a difference between arms.
SAMPLE SIZE DETERMINATION
Sample size calculations were based on detecting a clinically meaningful difference in the Patient Reported Outcomes Measurement Information System (PROMIS) Upper extremity computer adaptive test (CAT) of 4 points. PROMIS measures use a T-score metric with a mean of 50 and standard deviation of 10 in a reference population. A sample size of 133 per am, assuming a two-sided type I error rate of 0.05, will provide 90% power to detect a difference between arms of 4 points.
To conservatively account for 20% lost-to-follow-up or missing data on the primary outcome at 12 months, the investigators have inflated the sample size to 167 per arm, for a total target enrollment of 334.
A blinded sample size re-estimation based on the standard deviation of the primary outcome, after 100 participants have completed the 6 month follow-up, will be performed.
GENERAL APPROACH
Note: Statistical Analyses are described in depth in the Statistical Analysis Plan.
Descriptive statistics will summarize all baseline variables by arm. Specifically, continuous variables will be summarized using mean and standard deviation, for normally distributed variables, and median and IQR, for non-normally distributed variables. Categorical variables will be summarized with frequency and percentages. There will be no formal hypothesis testing for comparison of baseline characteristics between treatment arms.
Primary analyses of the primary outcome at 1 year will be assessed with a two-sided type I error rate of 0.05 for a MCID of 4 points. A false discovery rate (FDR) correction will be applied to analyses of all secondary outcomes to account for multiplicity.
ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)
Analysis for the primary aim will utilize a mixed effect model for the primary outcome, PROMIS Upper Extremity Function at 12 months, with a fixed effect for treatment arm and a random effect for site. Fixed effects will also include all variables considered in the randomization (site, sex, age), to control for imbalances in both the design and analysis. Incorporation of a random center effect will allow for separation of between site and within site variance components. Distributional assumptions will be assessed and transformations or inclusions of higher order terms may be considered, as appropriate.
ANALYSIS OF THE SECONDARY ENDPOINT(S)
Secondary analyses will employ similar methods for all secondary continuous outcomes. A generalized linear mixed effect model with Poisson distribution and log link will be used for the secondary count outcome, number of revisions, refractures, re-reductions, and reoperations. Distributional assumptions will be assessed, and a dichotomous version may be used instead if appropriate (any revisions, refractures, reductions, and reoperations vs never). Descriptive statistics will be used summarize satisfaction survey by treatment arm. Simple non-parametric test statistics or chi-squared test statistics may be used to compare ordinal and binary variables, respectively.
Exploratory analyses may also consider trajectories of the primary outcome measured over time. Fixed effects for baseline PROMIS Upper Extremity Function, time, treatment arm, and the interaction will be included in a linear mixed effect model with random patient nested in center effects.
A False Discovery Rate (FDR) correction will be applied to all secondary analyses to account for multiplicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immobilization in a cast without reduction
Procedure: Immobilization
closed reduction under conscious sedation followed by casting
Procedure: Reduction
closed reduction under conscious sedation followed by casting
immobilization in cast without reduction
PROMIS Pediatric CAT V2.0 - Physical Function- Upper Extremity
pediatric upper extremity function PROMIS computer adaptive test (PROMIS UE CAT)
Time frame: 1 year follow-up
PROMIS Pediatric CAT v2.0 - Physical Function- Upper Extremity
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, and 6 months
Disabilities of the Arm, Shoulder and Hand (DASH) S/PA
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, 6 months, and 1 year
PROMIS Pediatric V2.0 - Pain interference
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, and 1 year
Wong-Baker FACES Pain score
functional and patient reported outcomes
Time frame: 6 weeks and 3 months
PROMIS Pediatric V1.0- Global Health- Global Score
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, 6 months, and 1 year
PROMIS Pediatric V1.0 - Global Health- Fatigue Interference
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, 6 months, and 1 year
PROMIS Pediatric V1.0- Global Health - Pain Interference
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, 6 months, and 1 year
Number of revisions, refractures, re-reductions, and reoperations
clinical outcomes
Time frame: within 1 year
Other complications
functional and patient reported outcomes
Time frame: 1 year
Missed work or school
functional and patient reported outcomes
Time frame: 3 months
Satisfaction questionnaire
functional and patient reported outcomes
Time frame: 3 months, 6 months, and 1 year
Cosmesis
functional and patient reported outcomes
Time frame: 6 weeks, 3 months, 6 months, and 1 year
Radiographic alignment
functional and patient reported outcomes
Time frame: 6 weeks
Plan to share: No
Started Apr 2023 (actual). Primary completion is estimated for Dec 2030, 92 months after the start.
Of 128 non-industry interventional studies with no phase under Wrist Fractures, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 92 months is above that.
Counting every sponsor, half of 129 studies reached it within 24 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ann & Robert H Lurie Children's Hospital of Chicago →